PTC Therapeutics Names Morgan Stanley Biotech Banking Pioneer Jessica Chutter to Board of Directors
SHERIDAN, WYOMING - April 14, 2026 - PTC Therapeutics has appointed Jessica Chutter to its Board of Directors, adding a seasoned biotechnology investment banker who built and led Morgan Stanley's biotechnology franchise over an extensive tenure at the firm. The appointment brings capital markets expertise directly into PTC's governance structure at a time when the company operates multiple approved therapies across the U.S. and international markets and continues to invest in a diversified rare disease pipeline. Chutter is described by the company as a highly accomplished biotechnology investment banker with an extensive list of achievements. The board addition reinforces PTC's strategic focus on commercialization and financial positioning in specialty pharma.